2d illustrations and photos/iStock via Getty Images
Genetic medicines developer Metagenomi Technologies (MGX) has disclosed terms for a proposed $100M initial public offering.
In its latest SEC filing, Metagenomi said it was looking to offer 6.25M shares priced between $15 and $17 per share, which would raise $100M if priced at the midpoint. Underwriters would be granted a 30-day option to buy up to 937,500 additional shares to cover any overallotments.
Metagenomi hopes to list its shares on Nasdaq under the symbol MGX. Bookrunners include J.P. Morgan, Jefferies, TD Cowen, Wells Fargo Securities, BMO Capital Markets and Chardan.
Based in Emeryville, Calif., Metagenomi is focused on developing curative therapies using its proprietary metagenomics-derived genome editing tools. The company’s drug candidates are in preclinical development.
Metagenomi first filed for the IPO in January.
